GENB · Generate Biomedicines, Inc.
$13.91
+0.22 (+1.61%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”View the 10-Q filed Aug 6, 2026
Market Cap
$1.94B
Shares
128.35M
Volume · Oct 5
1.12M
Avg daily vol (3M)
1.03M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.91
Open$13.71
Day$13.45–14.06
Available close range$11.21–20.38
Avg vol 30d1.5M
Short int7.2M · 5.6% float · 7.2d
Short vol60%
Last earningsSep 15, 2026
DataFeb 2026–Oct 2026
Filing10-Q · Aug 6
The closing range uses available history since Feb 27, 2026; less than a full year is stored.
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-37.7%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$457.42M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+288.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.6%
Latest settlement · 7.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−10%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
29%
mid-range
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+8%
trailing
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+48% holders QoQ · +42 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.59% of float · ▼ -3.7% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — 13F breadth
Squeeze score
54
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
7.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−10%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
29%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+48% holders QoQ · +42 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.59% of float · ▼ -3.7% MoM · 7.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
86 holders — 13F breadth
Price context
position in its available closing range
Range low $11
Now $14 · 29%
Range high $20
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $457.4M | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GENB
this stock
Generate Biomedicines, Inc.
|
$1.94B | — | — | — | 5.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GENB | -6.7% | -15.1% | +7.9% | -7.4% | — |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -7.9% | -15.7% | -3.7% | -9.0% | — |